CIM
AMRX icon

Contravisory Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Contravisory Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,454
Closed -$254K – 367
2025
Q2 		$254K Hold
31,454
– – 0.05% 223
2025
Q1 		$264K Buy
+31,454
New +$263K 0.06% 208

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Contravisory Investment Management's AMRX Position: Q3 2025 in Review

Contravisory Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 31,454 shares — an estimated $254K sold.

Contravisory Investment Management first reported a position in AMRX in Q1 2025 and held it in 2 quarters. The position peaked at $264K in Q1 2025. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

  • Contravisory Investment Management reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 31,454 Amneal Pharmaceuticals shares in Q3 2025, an estimated $254K.
  • Contravisory Investment Management first reported a position in Amneal Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Contravisory Investment Management's Amneal Pharmaceuticals position peaked at $264K in Q1 2025.
  • 248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on Contravisory Investment Management's 13F filing for Q3 2025, filed 9 Oct 2025.